Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) generates a steady flow of news as a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its updates frequently center on progress in lung cancer trials with Reqorsa Gene Therapy (quaratusugene ozeplasmid) and preclinical advances in its diabetes program, GPX-002.
Investors following GNPX news can expect coverage of clinical trial milestones, such as dose-escalation results, Phase 2 expansion plans, new trial site additions, and peer-reviewed publications from studies like the Acclaim-1 and Acclaim-3 trials in non-small cell and small cell lung cancer. Company releases also highlight regulatory designations, including FDA Fast Track and Orphan Drug status for Reqorsa-based programs.
Another major news theme is preclinical and translational data. Genprex and its collaborators report findings on Reqorsa’s activity in specific lung cancer subtypes, including ALK-EML4-positive NSCLC models, as well as animal data showing TUSC2 upregulation, apoptosis induction, and survival benefits in xenograft studies. For diabetes, news often covers GPX-002 proof-of-concept data in Type 1 and Type 2 diabetes mouse and non-human primate models, including effects on beta-cell function and glucose control.
Genprex also issues corporate and regulatory announcements, such as registered direct offerings, at-the-market programs, warrant-related financings, and patent developments around Reqorsa combinations with PD-1 and PD-L1 antibodies. These items provide context on the company’s capital strategy and intellectual property position.
For readers tracking GNPX, this news stream offers insight into how Genprex’s gene therapy platforms are advancing through research, clinical development, regulatory interactions, and financing activities over time.
Genprex (NASDAQ: GNPX) provided a clinical update for its diabetes gene therapy program for GPX-002 on January 7, 2026, reporting preclinical progress and regulatory planning.
Key developments: preclinical proof-of-concept in Type 2 diabetes mouse and non-human primate models showing beta cell rejuvenation and normalized glucose; prior T1D models showed restored normal glucose and improved c-peptide/insulin metrics; manufacturing process transferred to CDMO partners; and a FDA meeting request submitted by end of 2025, with the meeting scheduled in Q1 2026 to discuss IND-enabling studies and next steps toward toxicology studies and cGMP clinical scale production.
Genprex (NASDAQ: GNPX) announced preliminary preclinical in vivo proof-of-concept data for GPX-002, a diabetes gene therapy, from Type 2 diabetic non-human primate (NHP) and mouse studies dated Jan 6, 2026. Key findings: one NHP treated via pancreatic duct infusion achieved normal glucose tolerance at seven months; a second NHP treated by direct pancreatic injection improved glucose tolerance at three months but did not normalize; T2D mice showed statistically significant glucose tolerance improvement at four weeks and restoration of normal glucose levels. Studies used an AAV vector carrying Pdx1 and MafA with an insulin promoter. Ongoing work includes toxicology and IND planning.
Genprex (NASDAQ: GNPX) reported publication of Acclaim-1 Phase 1 data in Clinical Lung Cancer on Nov 24, 2025, evaluating REQORSA (quaratusugene ozeplasmid) with osimertinib in advanced EGFR-mutant NSCLC after progression on prior osimertinib.
The Phase 1 dose-escalation (12 patients) found no dose-limiting toxicities, set a recommended Phase 2 dose (RP2D) of 0.12 mg/kg, and reported early signs of efficacy including one investigator-assessed partial remission continuing >32 months and two patients with prolonged progression-free survival.
Genprex (NASDAQ: GNPX) announced on November 19, 2025 that it added Gabrail Cancer Center in Canton, Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 studies of Reqorsa gene therapy (quaratusugene ozeplasmid) in lung cancer.
The company noted the Acclaim trials are supported by FDA Fast Track designation and said it expects to add additional sites over the coming months to expand patient access and expedite enrollment.
Genprex (NASDAQ: GNPX) announced the USPTO granted a U.S. patent covering use of its lead candidate Reqorsa gene therapy in combination with PD-L1 antibodies (example: Tecentriq) for cancer treatment, with protection through 2037. The patent is said to apply to Genprex's Acclaim-3 clinical trial in small cell lung cancer and is already granted in the U.S. and Korea. Genprex is pursuing additional patent applications in Europe, Canada, Brazil, China, and Israel, which the company says would extend protection to those trials if granted.
Genprex (NASDAQ: GNPX) announced that the European Patent Office has communicated its intent to grant a patent for the use of Reqorsa gene therapy (quaratusugene ozeplasmid) in combination with PD-1 antibodies to treat cancer (Nov 4, 2025).
This expands Genprex's patent estate that already includes granted patents for the same combination in the U.S., Japan, Mexico, Russia, Australia, Chile, China, and Singapore. Reqorsa is being developed alongside approved cancer drugs for lung cancer, with preclinical data showing complementarity with targeted drugs and immunotherapies.
The release cites EU and global lung cancer burden: ~250,000 EU deaths in 2021, 11.9% of new cancer diagnoses in EU-27 (2020), and GLOBOCAN 2022 estimates of ~2.48M new global cases and ~1.8M deaths.
Genprex (NASDAQ: GNPX) announced a registered direct offering of 377,780 shares at $9.00 per share for gross proceeds of about $3.4 million, priced at-the-market under Nasdaq rules. In a concurrent private placement, Genprex will issue unregistered short-term warrants to buy up to 755,560 shares at $8.75 per share, exercisable immediately and expiring 24 months after effectiveness of a resale registration statement, which could generate up to $6.6 million if fully exercised.
The offering is expected to close on or about October 29, 2025, H.C. Wainwright & Co. is placement agent, and net proceeds are intended for working capital and general corporate purposes. No assurance warrants will be exercised.
Genprex (NASDAQ: GNPX) announced collaborators presented positive preclinical data for Reqorsa® (quaratusugene ozeplasmid) at the 2025 AACR-NCI-EORTC conference (Oct 22–26, 2025).
University of Michigan data showed REQORSA upregulated TUSC2 in EML4-ALK+ NSCLC cell lines and patient-derived organoids, induced apoptosis including in alectinib-resistant cells, and that combining REQORSA with the ALK inhibitor alectinib increased apoptosis and improved survival in a human ALK+-EML4 mouse xenograft model.
The poster was presented Oct 25, 2025 and is available on the company website.
Genprex (NASDAQ:GNPX) announced a registered direct offering of 243,622 common shares at $11.21 per share for expected gross proceeds of approximately $2.7 million, priced at-the-market under Nasdaq rules.
In a concurrent private placement the company will issue unregistered short-term warrants to purchase up to 487,244 shares at an $11.00 exercise price, exercisable upon issuance and expiring 24 months after effectiveness of a resale registration statement; full exercise would generate up to $5.4 million additional gross proceeds. H.C. Wainwright & Co. is the exclusive placement agent. Proceeds are intended for working capital and general corporate purposes.
Genprex (NASDAQ: GNPX) collaborators will present positive preclinical data for Reqorsa® (quaratusugene ozeplasmid) at the 2025 AACR‑NCI‑EROTC conference in Boston on October 25, 2025. Studies show QO upregulates TUSC2 and induces apoptosis in ALK‑EML4 positive NSCLC models.
Key findings: QO alone and combined with alectinib reduced tumor volume by 79% in an NCI‑H2228 mouse model versus 60% for alectinib alone; QO increased caspase 3/7 activity, pro‑apoptotic markers, DNA fragmentation, and reduced colony formation. Results support a potential clinical trial pathway for REQORSA in ALK+ NSCLC.
FAQ
What is the current stock price of Genprex (GNPX)?
What is the market cap of Genprex (GNPX)?
